Market Research Logo

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • The report reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics and enlists all their major and minor projects
    • The report assesses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview
    Therapeutics Development
    Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics under Development by Companies
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Products under Development by Companies
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
    CSL Limited
    GeNeuro SA
    Mitsubishi Tanabe Pharma Corporation
    Octapharma AG
    Pfizer Inc.
    Shire Plc
    Teijin Pharma Limited
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fingolimod hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GL-2045 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GNbAC-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones
    Featured News & Press Releases
    Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
    Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy
    Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen
    Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
    May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Limited, H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc., H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Shire Plc, H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Limited, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2016
    Number of Products under Development by Companies, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report